bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.03.10.642527

Mechanisms of G-gene heterogeneities and a new method of genotyping of human metapneumovirus

CHAKRABORTY, A. K.
View original source ↗Export metadata ↓

Abstract

Human metapneumovirus (HMPV) is similar to AMPV and HRSV single-stranded RNA viruses. Controversy of HMPV G-gene heterogeneities due to duplication, deletion, recombination and termination codon mutation (TCM) complicated genotyping of a HMPV virus since 2015. Analysis of G-proteins from complete genomes suggested [~]88% sequence homology between A and B genotypes and still sub-genotyping possible. From extensive multi-alignment studies, we concluded that the G-gene (219aa) of HMPV A-genotype (MZ504961, LC671558) was duplicated 180nt first producing G-gene with 279aa protein of A1-genotype (OL794403, OP904094,) and then 69nt deletion occurred generating G-protein with 256aa protein of A2-genotype (OP904007, MZ851793). The few amino acids lower or higher A-genotype G-proteins like 265aa (LC769214), 261aa (PV052163), 254aa (MN745086), 236aa (KC403976), 228 (KJ627377), 222aa (AY327804), 217aa (OP904044) and 194aa (OL794386) are known due to generation of TCM. The destruction of termination codon (TC) used downstream alternate termination codon (ATC) extending few AAs but generation of new TC upstream produced short length G-proteins. The 228aa G protein was produced from 219aa lineage due to TCM and used ATC. The 254aa G-protein was generated from 256aaG lineage due to early TCM (CAA=TAA; C6870T). While 261aa G-protein was generated due to TCM (TAG=CAG) and used second ATC (TAA). The generation of B-genotype of HMPV occurred due to deletion as well as extensive editing to produce 236-242aa or smaller G-proteins [224aa (OL794406), 231aa (MZ504963), 233aa (MK989732), 236aa (KC562228), 237aa (MZ504966), 238aa (KC403971), 241aa (LC769218) and 242aa (KC562242)] but B-genotypes with 219aa, 256aa or 279aa lengths G-protein were not detected. The 236aa length G-protein found in both A-genotype and B-genotype as early as 1982. The 236aa A-genotype G-protein had different C-terminal sequence than 219aaG A-genotype, 256aaG A2-genotype and 279aaG A1-genotype. Thus, we concluded 236aaG clone might be primitive HMPV lineage. We observed G-protein of A -genotype likely ended with STMQK while B-genotype 236aa G-protein ended with YNQTS. The G-protein of B1-genotype preferred HTGISPK at the carboxy-end while B2-genotype ended with SSLSS. However, mutational difference was quite high between two 219aaG or 256aaG genotypes isolated 5-10 years gap. We suggested that a new genotype method like A.236.1.US.1, A.219.1.IN.1, A2.256.1.CN.1 or A1.279.1.JP.1. This is first bioinformatics worldwide analysis of HMPV WGS sequences suggesting a new method of genotyping and compared with very neglected Indian scenario.

Explore related subjects

bioinformaticsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

CHAKRABORTY, A. K.. 2025-03-13. Mechanisms of G-gene heterogeneities and a new method of genotyping of human metapneumovirus. https://doi.org/10.1101/2025.03.10.642527

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

AF3 Inspector: In-Browser 3D Model Visualization and Confidence Analytics for AlphaFold 3

AlphaFold 3 (AF3) has broadened the computational structural biology landscape by predicting all-atom complexes across proteins, nucleic acids, small-molecule ligands, and ions, including chemical modifications. For non-experts, Google provides a fully web-based service to utilize AlphaFold 3. Unfortunately, despite a flexible and rich interface for inputs, the server's outputs are incomplete and complicated for many users, as witnessed hands-on. Not all confidence metrics are displayed, and those that are shown do not present much interactivity; besides, only model number 1 is shown among the 5 produced by the software, and upon download the user finds the models are provided only in CIF format, which is not yet well-known especially among highly practical users. Here, we present the AlphaFold 3 Multi-Model Inspector (AF3 Inspector, https://pdbms.altervista.org/af3viewer/afviewer8.html), an open, client-side, zero-install web application designed to dissect, align, and interactively explore the complete ensemble of structural models produced by AlphaFold 3. Part of the PDB Manipulation Suite (https://pdbms.altervista.org/), the AF3 Inspector operates entirely within web browsers, meaning it is available out of the box in all devices and operating systems. AF3 Inspector delivers 3D visualization in various styles and colors for all models, overlay with backbone alignment if requested, interactive plots for pLDDT profiles, pAE matrices and contact maps, chain-pair interaction heatmaps, automated detection of ligands, ions and post-translational modifications, and rapid mmCIF-to-PDB conversion allowing users to download the more familiar files. The platform addresses critical practical considerations highlighted in recent community benchmarks, such as CASP16, and extends the lightweight, client-side biophysical toolkit paradigm established by the PDB Manipulation Suite (PDBMS).

bioinformatics↗
bioRxiv2026

PanVasc Research for AI assisted evidence analysis in panvascular intervention

Panvascular intervention research requires evidence workflows that preserve source identity, outcome definitions and observation windows. We developed PanVasc Research, an executable research framework, and evaluated a fixed local Qwen3-4B model using two complementary tasks. Fifty ClinicalTrials.gov records from five vascular query strata generated 200 source-fidelity tests with intact evidence or controlled removal of the requested source, primary outcome or timeframe, plus 50 clean controls. A separate 100-statement sample from the official NLI4CT test set assessed clinical-trial entailment and evidence selection against existing expert labels. Generic and checklist prompts used identical evidence and maximum generation budgets; each output was also evaluated with an input-only deterministic contract. Registry exact accuracy was 51/200 (25.5%) with the generic prompt and 77/200 (38.5%) with the checklist; intact-case agreement was 50/50 and 48/50. The rule baseline recovered 200/200 tuples. NLI label accuracy was 48/100 (48.0%) and 50/100 (50.0%), respectively. The source contract retained 35 and 31 incorrect NLI labels in the two arms. Registry references establish fidelity to a registration snapshot, while NLI4CT concerns breast-cancer trials and does not validate vascular expertise. The framework also retains provenance-recorded literature retrieval, structured research planning and local numerical analysis. These experiments support a bounded assessment of source handling and semantic failure, rather than a new foundation model or autonomous scientific discovery. A proposed endpoint representation identifies the additional domain annotation and independent validation required for a panvascular research model.

bioinformatics↗
bioRxiv2026

BiomiX 3.0: A user-friendly platform for democratized multi-omics integration with graph-based learning.

Background Multi-omics integration has emerged as a powerful strategy to decode the molecular complexity of biological systems. However, the diversity of available methods, each designed with distinct assumptions, objectives, and computational requirements, makes method selection, usage and interpretation challenging for nonexpert users. Here we present BiomiX 3.0, an updated version of the BiomiX platform that extends its integration capabilities with four additional methods: Similarity Network Fusion (SNF), NEighborhood-based Multi-Omics clustering (NEMO), Data Integration Analysis for Biomarker discovery using Latent variable approaches for Omics studies (DIABLO), and PRAMIGO (Phenotyping netwoRk Application for Multi-omics InteGratiOn), a novel supervised heterogeneous graph transformer (HGT) introduced in this work. Results We benchmarked all five methods, MOFA, DIABLO, SNF, NEMO, and PRAMIGO, on two independent multiomics datasets derived from a Chronic Lymphocytic Leukemia (CLL) cohort comparing IGHV-mutated and unmutated patients, and a pulmonary tuberculosis (PTB) cohort versus healthy controls. Supervised methods (DIABLO, PRAMIGO) consistently achieved higher condition-specific discrimination as measured by the Adjusted Rand Index (ARI) and the Adjusted Mutual Information (AMI). In contrast, unsupervised methods (SNF, NEMO) revealed alternative patient stratifications driven by independent sources of biological variance while MOFA performed in a semi-supervised way occupies an intermediate position, capturing latent factors that explain both disease-associated and orthogonal sources of variance. Systematic gene-centric analysis of the top-ranked features prioritized by each method was supported by manual biological annotation of shared and method-specific signals. Across cohorts, we annotated 154 shared features (116 genes, 38 metabolites) and 60 method-unique features per cohort, demonstrating that no single integration strategy captures the full landscape of biologically relevant signals. In the CLL cohort, shared features spanned B-cell receptor biology, innate immune signaling, RAS/MAPK activation, and epigenetic regulation, while methodunique features revealed supervised-method-specific insights into vesicle trafficking (DIABLO), immune checkpoints (MOFA), and ncRNA regulation (PRAMIGO). In the PTB cohort, a convergent interferon/innate immune signature dominated shared features across all methods. Still, method-unique analysis uncovered DIABLO-specific acylcarnitine metabolic reprogramming, MOFA-specific restoration of lysosomal trafficking, and PRAMIGO-specific {gamma}{delta} T-cell and immunoglobulin repertoire diversity. Across both cohorts, SNF and NEMO proved useful for detecting biological and technical sources of variation that were orthogonal to the primary condition of interest. Ultimately, PRAMIGO uniquely enables the construction of heterogeneous graphs modeling cross-modal molecular interactions, uncovering epigenetic co-regulation programs in CLL and multi-omics inflammatory modules in PTB that are difficult to identify using conventional integration approaches. Conclusions BiomiX 3.0 provides a graphical user interface (GUI) multi-method integration environment that democratizes access to state-of-the-art multi-omics analysis. By combining both unsupervised and supervised integration strategies within a unified platform and introducing graph-based learning through PRAMIGO, BiomiX 3.0 enables researchers across disciplines with complementary tools to interrogate the biological sources of variation in their data, without requiring bioinformatics expertise.

bioinformatics↗